myriad genetics
-
Myriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing Platform
Myriad to support MD Anderson researchers studying metastatic renal cell carcinoma treatment selection and response
-
Myriad Genetics Expands Consumer Access to Genetic Testing with Acquisition of Gateway Genomics and Its Market-Leading SneakPeek® Early Gender DNA Test
$67.5 million tuck-in acquisition strengthens Myriad’s Women’s Health portfolio of prenatal products.
-
Myriad Genetics Reports Third Quarter Financial Results
Myriad Genetics announced financial results for its third quarter ended September 30, 2022 and provided an update on…
-
Myriad Genetics Teams Up with Epic to Make Genetic Testing Accessible to More Patients with Electronic Health Record (EHR) Integration
Healthcare providers can easily order Myriad’s genetic tests for the more than 250 million patients within Epic’s network
-
Myriad Genetics Named to Fast Company’s Annual List of World’s Most Innovative Companies
Myriad to establish new Walter Gilbert Research and Innovation Center Company also cited among 2022 Top Workplaces USA…
-
Myriad Genetics Receives FDA Approval of BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Early Breast Cancer
BRACAnalysis CDx is now the only germline test approved by FDA as a companion diagnostic for treatment of…
-
Myriad Genetics Advances Precision Oncology with New Precise™ Solutions, Combines Genetic Insights from Multiple Tests to Guide Treatment Decisions and Improve Patient Care
Company launches Precise™ Tumor test, part of a comprehensive suite combining germline, tumor and companion diagnostics in one…
-
Myriad Genetics Reports Fourth Quarter 2021 Results, Provides Updates on Product Performance and Growth Initiatives
Myriad Genetics announced financial results for its fourth quarter and year ended Dec. 31, 2021.
-
Myriad Genetics Promotes Nicole Lambert to Chief Operating Officer
Myriad Genetics Promotes Nicole Lambert to Chief Operating Officer
-
Myriad Genetics Reports Third Quarter 2021 Results, Continues Strong Execution of Strategic Growth & Transformation Plans
Myriad Genetics announced financial results for its third quarter ended September 30, 2021 and provided an update on…
Call to Action
Post Category
- BioUtah COVID-19 Analysis
- BioUtah News
- Business Tools & Resources
- Call to Action
- chair
- COVID-19 Legislation
- COVID-19 Updates
- Economic Developments
- Events
- Events
- Feature
- Featured Members
- Federal News
- Funding
- Funding
- Guests Posts
- HHS/FDA & Other Regulatory
- HR
- Industry News
- Life Sciences Events
- Life Sciences Industry News
- Newsletters
- Non-chair
- Policy News
- Press Releases
- State News
- Utah's Life Sciences Companies
- Workplace Safety
Latest Posts
- Lumea Named Best New Biopsy Technology Solution in 2026 MedTech Breakthrough Awards
- Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert
- BlueWind Medical Secures $47.8 Million Financing to Accelerate Commercialization of Revi® System
- PhotoPharmics Announces Last Patient Last Visit in Pivotal, Phase 3, Light for PD Clinical Trial; Company to Present Topline Data at World Parkinson Congress
- AFTER SUCCESSFUL FDA MEETING, CLENE FILING ACCELERATED APPROVAL NDA FOR ALS
